Current Month 2005
Article Features
  Moderate Alcohol Use Linked to Increase in Breast Cancer Risk
Poor Understanding of Coverage Deters Breast Cancer Screening
Breast Tumor's Biological Traits Guide Hormone Therapy
High Risk of Second Cancers in Survivors of Childhood Soft Tissue Sarcomas
Herbal Medicine May Alter Cell Response to Cancer Therapeutic Agents
Breast CT May Improve Upon Mammography
Untreated Low-Grade DCIS Poses Long-Term Risk
Contraceptive Hormone Decreases Ability of Breast Cancer to Spread
Genetic Testing Divides Families
Japanese Women Found to Have Lower Recurrence of Breast Cancer
Access to Mammography May Worsen
Method Hold Promise for Identifying Markers of Non-Metastatic vs. Metastatic Breast Cancer
Molecular Change Occurring During Brain Tumor Progression Also Evident in Breast Cancer
New Breast Shield Reduces Radiation To Female Breast During Chest CT By Up To 73%
Soy-Rich Diet
Tamoxifen-Like Drug Suggests New Ways to Selectively Block Estrogen
Tamoxifen Shows No Benefit, Risk for Breast Cancer Survivors' Heart Health
Test Predicts Risk of Blood Clots in Women Taking Tamoxifen
Breast Cancer Detector That Uses Electricity Instead of X-Rays Under Study


Herceptin Found to Significantly Reduce Breast Cancer Recurrence for Some Women

Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin®) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.

Dr. Edward Romond, associate professor of medicine at the University of Kentucky College of Medicine and UK Markey Cancer Center, acts as principal investigator on the study and the National Surgical Adjuvant Breast and Bowel Project (NSABP) study chair.

"For women with this type of aggressive breast cancer, the addition of trastuzumab to chemotherapy appears to virtually reverse prognosis from unfavorable to good. We owe a huge debt of gratitude to the women whose participation in these trials has made it possible to show the substantial benefit of combining trastuzumab with chemotherapy for adjuvant treatment of women with HER-2 positive breast cancer," said Romond.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon